Profile data is unavailable for this security.
About the company
Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).
- Revenue in AUD (TTM)8.67m
- Net income in AUD-69.00m
- Incorporated2014
- Employees--
- LocationParadigm Biopharmaceuticals LtdLevel 15, 500 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39629-5566
- Fax+61 39629-5466
- Websitehttps://paradigmbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTR Pharma Ltd | -100.00bn | -100.00bn | 61.96m | -- | -- | 19.53 | -- | -- | -- | -- | -- | 0.0451 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -41.65 | -- | -- | -- |
Inoviq Ltd | 751.54k | -6.51m | 66.17m | 85.00 | -- | 3.30 | -- | 88.04 | -0.0708 | -0.0708 | 0.0082 | 0.182 | 0.0339 | 2.10 | 0.873 | -- | -29.33 | -47.68 | -32.18 | -50.76 | 95.07 | -- | -866.27 | -2,527.82 | 4.93 | -- | 0.0332 | -- | 119.59 | 153.31 | 50.71 | -- | -- | -- |
Percheron Therapeutics Ltd | 624.51k | -10.85m | 72.12m | 8.00 | -- | 4.38 | -- | 115.49 | -0.0157 | -0.0157 | 0.0009 | 0.0182 | 0.0328 | -- | 0.3224 | -- | -56.94 | -72.09 | -66.58 | -81.73 | -- | -- | -1,737.37 | -6,558.90 | -- | -- | 0.001 | -- | 1,026.16 | 72.03 | -95.81 | -- | -- | -- |
Neurotech International Ltd | 1.28m | -4.98m | 82.41m | -- | -- | 15.07 | -- | 64.51 | -0.0058 | -0.0058 | 0.0015 | 0.0054 | 0.1826 | -0.1149 | 5.67 | -- | -71.23 | -197.33 | -74.66 | -255.24 | 100.07 | 79.57 | -390.03 | -1,043.88 | 18.35 | -- | 0.00 | -- | 106.22 | 83.24 | -131.75 | -- | -- | -- |
Argenica Therapeutics Ltd | 92.21k | -4.67m | 106.38m | -- | -- | 12.93 | -- | 1,153.70 | -0.0511 | -0.0511 | 0.001 | 0.0665 | 0.0109 | -- | 0.6384 | -- | -55.31 | -- | -69.00 | -- | -- | -- | -5,067.62 | -- | -- | -6,663.20 | 0.00 | -- | 2,340.00 | -- | -17.71 | -- | -- | -- |
Paradigm Biopharmaceuticals Ltd | 8.67m | -69.00m | 108.44m | -- | -- | 3.22 | -- | 12.51 | -0.2296 | -0.2296 | 0.0288 | 0.0962 | 0.1298 | -- | 2.25 | -- | -103.34 | -40.96 | -127.58 | -44.13 | 99.87 | -- | -796.30 | -466.85 | -- | -348.76 | 0.0085 | -- | 7.58 | 25.42 | -32.26 | -- | -- | -- |
Proteomics International LaboratoriesLtd | 1.44m | -5.90m | 123.14m | -- | -- | 21.49 | -- | 85.22 | -0.0518 | -0.0518 | 0.0129 | 0.0437 | 0.1817 | -- | 11.13 | -- | -75.75 | -57.79 | -87.11 | -67.57 | -- | -- | -416.78 | -229.69 | -- | -283.47 | 0.0088 | -- | -14.64 | 4.12 | -24.20 | -- | 89.02 | -- |
Holder | Shares | % Held |
---|---|---|
Allianz Global Investors GmbHas of 17 May 2024 | 21.31m | 6.08% |
Allianz Global Investors Asia Pacific Ltd.as of 30 Apr 2024 | 13.91m | 3.97% |
RBC Global Asset Management (Asia) Ltd.as of 31 May 2024 | 10.36m | 2.96% |
Netwealth Investments Ltd.as of 14 Aug 2023 | 7.40m | 2.11% |
Allianz Global Investors Singapore Ltd.as of 30 Apr 2024 | 2.79m | 0.80% |
Pictet Asset Management SAas of 31 Dec 2023 | 2.25m | 0.64% |
Norges Bank Investment Managementas of 31 Dec 2023 | 2.17m | 0.62% |
Perennial Value Management Ltd.as of 14 Aug 2023 | 1.65m | 0.47% |
Pictet Asset Management (Singapore) Pte Ltd.as of 31 Dec 2023 | 906.94k | 0.26% |
SSgA Funds Management, Inc.as of 03 Jul 2024 | 275.49k | 0.08% |